Amgen (AMGN) announced new data from the Phase 3, registrational MINT trial evaluating the efficacy and safety of Uplinza in adults living with generalized myasthenia gravis. The results ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
